{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:51:03Z","timestamp":1787169063329,"version":"build-2736575974"},"reference-count":18,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Soonchunhyang University research fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab\/bevacizumab in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: We would like to introduce the cases of two patients who underwent bevacizumab reduction or discontinuation when VB occurred after atezolizumab\/bevacizumab. Results: VB occurred in two patients who showed good tumor response after atezolizumab\/bevacizumab treatment, and all VBs were successfully treated with endoscopic variceal ligations. In the first patient, VB did not occur as the tumor response decreased after a 50% reduction in bevacizumab. In the second patient, VB occurred again after a 50% bevacizumab reduction, so bevacizumab was discontinued and treatment with atezolizumab alone has been successfully maintained. Conclusions: Accordingly, we would like to suggest that considering bevacizumab dose reduction instead of changing to tyrosine kinase inhibitor may be a good clinical choice in atezolizumab\/bevacizumab patients who develop VB.<\/jats:p>","DOI":"10.3390\/medicina60010157","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:03:26Z","timestamp":1705291406000},"page":"157","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab\/Bevacizumab: Case Reports"],"prefix":"10.3390","volume":"60","author":[{"given":"Kyeong-Min","family":"Yeom","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Soonchunhyang University School of Medicine, Bucheon 14584, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Gi","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Soonchunhyang University School of Medicine, Bucheon 14584, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-0381","authenticated-orcid":false,"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Soonchunhyang University School of Medicine, Bucheon 14584, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8694-777X","authenticated-orcid":false,"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Soonchunhyang University School of Medicine, Bucheon 14584, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Soonchunhyang University School of Medicine, Bucheon 14584, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.17998\/jlc.2023.09.04","article-title":"A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma","volume":"23","author":"Lee","year":"2023","journal-title":"J. Liver Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","article-title":"The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma","volume":"23","author":"Lee","year":"2023","journal-title":"J. Liver Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.17998\/jlc.2022.03.28","article-title":"Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma","volume":"22","author":"Kim","year":"2022","journal-title":"J. Liver Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Korean Liver Cancer Association (2023). National Cancer Center, 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J. Liver Cancer, 23, 1126.","DOI":"10.3348\/kjr.2022.0822"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis of More Than 20000 Patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fang, P., Hu, J.-H., Cheng, Z.-G., Liu, Z.-F., Wang, J.-L., and Jiao, S.-C. (2012). Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049717"},{"key":"ref_8","unstructured":"European Medicines Agency (2022). Avastin: EPAR\u2014Product Information, European Medicines Agency."},{"key":"ref_9","unstructured":"FDA (2022). Avastin US Prescribing Information (USPI), Genentech, Inc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","article-title":"Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?","volume":"53","author":"Thabut","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1200\/JCO.2005.23.754","article-title":"Surgical Resection after Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab","volume":"23","author":"Ellis","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12328-022-01605-9","article-title":"Two cases of rapid progression of esophageal varices after atezolizumab\u2013bevacizumab treatment for hepatocellular carcinoma","volume":"15","author":"Furusawa","year":"2022","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"948293","DOI":"10.3389\/fonc.2022.948293","article-title":"Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review","volume":"12","author":"Suzuki","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"454","DOI":"10.21873\/invivo.13099","article-title":"Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial","volume":"37","author":"Lee","year":"2023","journal-title":"In Vivo"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/nop\/npv065","article-title":"Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cgh.2018.03.012","article-title":"Screening and Surveillance of Varices in Patients with Cirrhosis","volume":"17","author":"Jakab","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1016\/j.cgh.2022.07.035","article-title":"Risk of Variceal Bleeding in Patients with Advanced Hepatocellular Carcinoma Receiving Atezolizumab\/Bevacizumab","volume":"21","author":"Ha","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/157\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:54Z","timestamp":1760104014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["medicina60010157"],"URL":"https:\/\/doi.org\/10.3390\/medicina60010157","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]}}}